您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > LY2886721
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LY2886721
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LY2886721图片
CAS NO:1262036-50-9
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
5mg电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
LY2886721 是一种有效的,选择性的,口服活性的 β 位淀粉样蛋白前体蛋白裂解酶 1 (BACE1) 抑制剂,对重组人BACE1IC50为 20.3 nM。LY2886721 对BACE1的选择性高于对组织蛋白酶 D,胃蛋白酶和肾素的选择性,但缺乏对BACE2(IC50为 10.2 nM) 的选择性。LY2886721 可穿越血脑屏障,并可用于阿尔茨海默氏病的研究。
生物活性

LY2886721 is a potent, selective and orally activebeta-site amyloid precursor protein cleaving enzyme 1 (BACE1)inhibitor with anIC50of 20.3 nM for recombinant humanBACE1. LY2886721 is selectivity againstcathepsin D, pepsin, andrenin, but lacking selectivity againstBACE2(IC50of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment[1].

IC50& Target

IC50: 20.3 nM (Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1)); 10.2 nM (BACE2)[1]

体外研究
(In Vitro)

Overnight exposure of HEK293Swe cells to increasing concentrations of LY2886721 shows a concentration-dependent decrease in the amount of Aβ secreted into the condition medium. Consistent with a mechanism of BACE inhibition, the EC50s for inhibition of Aβ1-40and Aβ1-42are essentially identical, 18.5 and 19.7 nM, respectively[1].
Overnight exposure of PDAPP neuronal cultures to an increasing concentration of LY2886721 produces a concentration-dependent decrease in Aβ production. As observed in HEK293Swe cells, the EC50s for inhibition of Aβ1-40and Aβ1-42are comparable in PDAPP neuronal cultures at ~10 nM[1].

体内研究
(In Vivo)

LY2886721 (3-30 mg/kg; oral administration; PDAPP mice) treatment significantly reduces the hippocampal and cortical levels of Aβ1-x. LY2886721 treatment results in significant reduction of brain parenchymal levels of C99 and sAPPβ[1].

Animal Model:Female hemizygous APPV717F transgenic mice (PDAPP) (2-3 months old)[1]
Dosage:3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:Oral administration
Result:Hippocampal and cortical levels of Aβ1-xwere significantly reduced.
Clinical Trial
分子量

390.41

性状

Solid

Formula

C18H16F2N4O2S

CAS 号

1262036-50-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : ≥ 16.67 mg/mL(42.70 mM)

H2O :< 0.1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble)

*"≥" means soluble, but saturation unknown.

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.5614 mL12.8070 mL25.6141 mL
5 mM0.5123 mL2.5614 mL5.1228 mL
10 mM0.2561 mL1.2807 mL2.5614 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 2 mg/mL (5.12 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (5.12 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。